{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:45:17Z","timestamp":1792154717047,"version":"4.4.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T00:00:00Z","timestamp":1662595200000},"content-version":"am","delay-in-days":342,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.schres.2021.07.040","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T13:21:09Z","timestamp":1631107269000},"page":"142-155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Antipsychotic treatment strategies for acute phase and treatment resistance in schizophrenia: A systematic review of the guidelines and algorithms"],"prefix":"10.1016","volume":"236","author":[{"given":"Yutaro","family":"Shimomura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhei","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takefumi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Mimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyoshi","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.schres.2021.07.040_bb0005","doi-asserted-by":"crossref","first-page":"276","DOI":"10.5455\/bcp.20140923115118","article-title":"Treatment guidelines for patients with schizophrenia or psychotic disorder who are hospitalized in a psychiatry clinic","volume":"24","author":"Alptekin","year":"2014","journal-title":"Klin. Psikofarmakol. Bul."},{"issue":"1","key":"10.1016\/j.schres.2021.07.040_bb0010","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/acps.12742","article-title":"International trends in clozapine use: a study in 17 countries","volume":"136","author":"Bachmann","year":"2017","journal-title":"Acta Psychiatr. Scand."},{"issue":"1","key":"10.1016\/j.schres.2021.07.040_bb0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0269881119889296","article-title":"Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology","volume":"34","author":"Barnes","year":"2019","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.schres.2021.07.040_bb0020","series-title":"Analysis AGREE II: Advancing Guideline Development, Reporting and Evaluation in Health Care","first-page":"839","volume":"182(18)","author":"Brouwers","year":"2010"},{"issue":"2","key":"10.1016\/j.schres.2021.07.040_bb0025","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/01.jcp.0000117422.05703.ae","article-title":"Dose response and dose equivalence of antipsychotics","volume":"24","author":"Davis","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1\u20133","key":"10.1016\/j.schres.2021.07.040_bb0030","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.schres.2015.04.024","article-title":"Dose escalation of antipsychotic drugs in schizophrenia: a meta-analysis of randomized controlled trials","volume":"166","author":"Dold","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2021.07.040_bb0035","series-title":"German Association for Psychiatry, Psychotherapy and Psychosomatics, DGPPN (Deutsche Gesellschaft f\u00fcr Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e. V.) (Publisher) S3 Guideline for Schizophrenia AWMF Register No. 038-009","first-page":"1","author":"Gaebel","year":"2019"},{"issue":"5","key":"10.1016\/j.schres.2021.07.040_bb0040","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/0004867416641195","article-title":"Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders","volume":"50","author":"Galletly","year":"2016","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2021.07.040_bb0045","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/wps.20387","article-title":"Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis","volume":"16","author":"Galling","year":"2017","journal-title":"World Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2021.07.040_bb0050","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1192\/bjp.bp.110.081471","article-title":"Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial","volume":"199","author":"Girgis","year":"2011","journal-title":"Br. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2021.07.040_bb0055","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4103\/0019-5545.196973","article-title":"Clinical practice guidelines for management of schizophrenia","volume":"59","author":"Grover","year":"2017","journal-title":"Indian J. Psychiatry"},{"key":"10.1016\/j.schres.2021.07.040_bb0060","series-title":"NI of MH. ECDEU Assessment Manual for Psychopharmacology\/William Guy. Vol Rev. 1976","year":"1976"},{"issue":"416","key":"10.1016\/j.schres.2021.07.040_bb0065","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1034\/j.1600-0447.107.s416.5.x","article-title":"The clinical global impression-schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia","volume":"107","author":"Haro","year":"2003","journal-title":"Acta Psychiatr. Scand. Suppl."},{"issue":"5","key":"10.1016\/j.schres.2021.07.040_bb0070","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3109\/15622975.2012.696143","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance","volume":"13","author":"Hasan","year":"2012","journal-title":"World J. Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2021.07.040_bb0075","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","article-title":"Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology","volume":"174","author":"Howes","year":"2017","journal-title":"Am. J. Psychiatry"},{"issue":"10","key":"10.1016\/j.schres.2021.07.040_bb0080","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S2215-0366(18)30252-9","article-title":"Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study","volume":"5","author":"Kahn","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2021.07.040_bb0085","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.schres.2021.07.040_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjopen-2016-013881","article-title":"Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode","volume":"7","author":"Keating","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.schres.2021.07.040_bb0095","series-title":"The American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia","volume":"Vol 177","author":"Keepers","year":"2020"},{"issue":"2","key":"10.1016\/j.schres.2021.07.040_bb0100","first-page":"309","article-title":"Treatment of neuroleptic-resistant schizophrenic relapse","volume":"29","author":"Kinon","year":"1993","journal-title":"Psychopharmacol. Bull."},{"issue":"3","key":"10.1016\/j.schres.2021.07.040_bb0105","doi-asserted-by":"crossref","first-page":"386","DOI":"10.9758\/cpn.2020.18.3.386","article-title":"Korean medication algorithm for schizophrenia 2019, second revision: treatment of psychotic symptoms","volume":"18","author":"Lee","year":"2019","journal-title":"Clin. Psychopharmacol. Neurosci."},{"issue":"2","key":"10.1016\/j.schres.2021.07.040_bb0110","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/schbul\/sbu001","article-title":"Dose equivalents for second-generation antipsychotics: the minimum effective dose method","volume":"40","author":"Leucht","year":"2014","journal-title":"Schizophr. Bull."},{"issue":"3","key":"10.1016\/j.schres.2021.07.040_bb0115","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/schbul\/sbv019","article-title":"The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics","volume":"41","author":"Leucht","year":"2015","journal-title":"Schizophr. Bull."},{"issue":"10","key":"10.1016\/j.schres.2021.07.040_bb0120","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1176\/appi.ajp.2017.16121358","article-title":"Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors","volume":"174","author":"Leucht","year":"2017","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2021.07.040_bb0125","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1176\/appi.ajp.2019.19010034","article-title":"Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia","volume":"177","author":"Leucht","year":"2020","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2021.07.040_bb0130","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/sj.npp.1300157","article-title":"Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine","volume":"28","author":"Lieberman","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"10.1016\/j.schres.2021.07.040_bb0135","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.4088\/JCP.16m10698","article-title":"Lurasidone dose escalation in early nonresponding patients with schizophrenia: a randomized, placebo-controlled study","volume":"77","author":"Loebel","year":"2016","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2021.07.040_bb0140","series-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement","first-page":"1006","volume":"62","author":"Moher","year":"2009"},{"key":"10.1016\/j.schres.2021.07.040_bb0145","series-title":"Psychosis and Schizophrenia in Adults: Treatment and Management: Updated Edition 2014","year":"2014"},{"issue":"Xx","key":"10.1016\/j.schres.2021.07.040_bb0150","first-page":"1","article-title":"ASHP therapeutic position statement on the use of antipsychotic medications in the treatment of adults with schizophrenia and schizoaffective disorder","author":"Noel","year":"2020","journal-title":"Am. J. Health Pharm."},{"issue":"1","key":"10.1016\/j.schres.2021.07.040_bb0155","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/HRP.0b013e31827fd915","article-title":"The psychopharmacology algorithm project at the Harvard South Shore Program","volume":"21","author":"Osser","year":"2013","journal-title":"Harv. Rev. Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2021.07.040_bb0160","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1177\/0706743717720448","article-title":"Guidelines for the pharmacotherapy of schizophrenia in adults","volume":"62","author":"Remington","year":"2017","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/j.schres.2021.07.040_bb0165","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.4088\/JCP.15m10490","article-title":"Increasing versus maintaining the dose of olanzapine or risperidone in schizophrenia patients who did not respond to a modest dosage: a double-blind randomized controlled trial","volume":"77","author":"Sakurai","year":"2016","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2021.07.040_bb0170","article-title":"Pharmacological treatment of schizophrenia: Japanese expert consensus","author":"Sakurai","year":"2021","journal-title":"Pharmacopsychiatry"},{"issue":"7","key":"10.1016\/j.schres.2021.07.040_bb0175","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1176\/appi.ajp.2015.14101329","article-title":"Early improvement as a predictor of later response to antipsychotics in schizophrenia: a diagnostic test review","volume":"172","author":"Samara","year":"2015","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2021.07.040_bb0180","article-title":"Increasing antipsychotic dose for non response in schizophrenia","volume":"2018","author":"Samara","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"issue":"3","key":"10.1016\/j.schres.2021.07.040_bb0185","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/schbul\/sby095","article-title":"How many patients with schizophrenia do not respond to antipsychotic drugs in the short term? An analysis based on individual patient data from randomized controlled trials","volume":"45","author":"Samara","year":"2019","journal-title":"Schizophr. Bull."},{"issue":"1\u20133","key":"10.1016\/j.schres.2021.07.040_bb2000","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.schres.2013.07.003","article-title":"Randomized trial of clozapine vs. risperidone in treatment-na\u00efve first-episode schizophrenia: results after one year","volume":"149","author":"Sanz-Fuentenebro","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2021.07.040_bb0195","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.psychres.2018.06.070","article-title":"The impact of delay in clozapine initiation on treatment outcomes in patients with treatment-resistant schizophrenia: a systematic review","volume":"268","author":"Shah","year":"2018","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2021.07.040_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.schres.2019.09.013","article-title":"Antipsychotic treatment in the maintenance phase of schizophrenia: an updated systematic review of the guidelines and algorithms","volume":"215","author":"Shimomura","year":"2020","journal-title":"Schizophr. Res."},{"issue":"11","key":"10.1016\/j.schres.2021.07.040_bb0205","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1177\/0706743717718167","article-title":"Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis","volume":"62","author":"Siskind","year":"2017","journal-title":"Can. J. Psychiatr."},{"issue":"8","key":"10.1016\/j.schres.2021.07.040_bb0210","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1177\/0004867418772351","article-title":"Augmentation strategies for clozapine refractory schizophrenia: a systematic review and meta-analysis","volume":"52","author":"Siskind","year":"2018","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2021.07.040_bb0215","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1017\/S109285291300014X","article-title":"\u201cMeta-guidelines\u201d for the management of patients with schizophrenia","volume":"18","author":"Stahl","year":"2013","journal-title":"CNS Spectr."},{"issue":"4","key":"10.1016\/j.schres.2021.07.040_bb0220","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1192\/bjp.bp.110.083907","article-title":"Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia","volume":"199","author":"Suzuki","year":"2011","journal-title":"Br. J. Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.schres.2021.07.040_bb0225","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.schres.2011.11.021","article-title":"Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms","volume":"134","author":"Takeuchi","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2021.07.040_bb0230","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jpsychires.2016.06.005","article-title":"A preliminary examination of the validity and reliability of a new brief rating scale for symptom domains of psychosis: brief evaluation of psychosis symptom domains (BE-PSD)","volume":"80","author":"Takeuchi","year":"2016","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.schres.2021.07.040_bb0235","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2017.08.012","article-title":"Rapid vs. slow antipsychotic initiation in schizophrenia: a systematic review and meta-analysis","volume":"193","author":"Takeuchi","year":"2018","journal-title":"Schizophr. Res."},{"issue":"6","key":"10.1016\/j.schres.2021.07.040_bb0240","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/s41386-018-0278-3","article-title":"Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia","volume":"44","author":"Takeuchi","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2021.07.040_bb0245","doi-asserted-by":"crossref","DOI":"10.1093\/schbul\/sbaa063","article-title":"Antipsychotic dose in acute schizophrenia: a meta-analysis","author":"Takeuchi","year":"2020","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2021.07.040_bb0250","series-title":"The Maudsley Prescribing Guidelines","author":"Taylor","year":"2018"},{"issue":"7","key":"10.1016\/j.schres.2021.07.040_bb0255","first-page":"521","article-title":"Ministry of Health clinical practice guidelines: schizophrenia","volume":"52","author":"Verma","year":"2011","journal-title":"Singap. Med. J."},{"key":"10.1016\/j.schres.2021.07.040_bb0260","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jpsychires.2018.08.002","article-title":"ECT augmentation of clozapine for clozapine-resistant schizophrenia: a meta-analysis of randomized controlled trials","volume":"105","author":"Wang","year":"2018","journal-title":"J. Psychiatr. Res."},{"issue":"5","key":"10.1016\/j.schres.2021.07.040_bb0265","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.4088\/JCP.16r10782","article-title":"Clozapine augmentation with antiepileptic drugs for treatment-resistant schizophrenia: a meta-analysis of randomized controlled trials","volume":"78","author":"Zheng","year":"2017","journal-title":"J. Clin. Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2021.07.040_bb0270","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.euroneuro.2017.06.011","article-title":"How well do patients with a first episode of schizophrenia respond to antipsychotics: a systematic review and meta-analysis","volume":"27","author":"Zhu","year":"2017","journal-title":"Eur. Neuropsychopharmacol."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996421003133?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996421003133?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:43:29Z","timestamp":1760298209000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996421003133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":54,"alternative-id":["S0920996421003133"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2021.07.040","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antipsychotic treatment strategies for acute phase and treatment resistance in schizophrenia: A systematic review of the guidelines and algorithms","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2021.07.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}